Vasomotor Symptoms Market size was estimated at over USD 4.2 billion in 2024 and is poised to reach USD 10.4 billion by the end of 2037, expanding at a CAGR of 7.9% during the forecast timeline, i.e., 2025-2037. In 2025, the industry size of the vasomotor symptoms is evaluated at USD 4.5 billion.
The rising population of older women around the world is a major feedstock in the market. Women going through menopause are the targeted objective of this condition and is a most common issue among older women. Thus, the rising incidence of menopause is driving demand in this sector by creating a large pool of patients. According to the WHO report, published in October 2024, around 26% of the total female population of the world was accounted to be postmenopausal women aged 50 or over in 2021. The report further highlighted an increment of 22% in this amount from the last 10 years and it is expected to grow significantly.
According to an NLM article, published in May 2021, vasomotor symptoms (VMS) or hot flushes occur among 80% of women, who are at their menopausal transition stage. Growing awareness about the risk factors that come along with this state of life in a woman’s life is encouraging them to cultivate pre-assured resources. Thus, the inflation in demand for associated medical advice and treatment is propelling growth in the vasomotor symptoms market. Moreover, the widespread availability of therapies and drugs to manage these symptoms is contributing to the expansion of this sector.
Regional Prevalence of Vasomotor Symptoms (VMS)
|
Asia |
22-63% |
|
North America |
36-50% |
|
Europe |
74% |
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.9% |
|
Base Year Market Size (2024) |
USD 4.2 billion |
|
Forecast Year Market Size (2037) |
USD 10.4 billion |
|
Regional Scope |
|
Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Stores)
Based on the distribution channel, hospital pharmacies segment is anticipated to capture vasomotor symptoms market share of around 61.5% by the end of 2037. The assurance of availing all certified drugs on hospital premises is also a factor in building consumer trust, attracting pharma companies to invest in this segment. Moreover, the significant amount that patients spend on these pharmacies is the growth factor of this distribution channel. According to the NLM report, published in November 2022, a considerable part of the total pharmaceutical expenditure goes to hospital pharmacies. It further stated that around 20-50% of the total third-party buyers in Europe countries are associated with this segment.
Therapy Type (Hormonal, Non-Hormonal)
In terms of therapy type, the hormonal segment is estimated to hold a significant share of the vasomotor symptoms market by the end of 2037. Despite the increasing demand for non-hormonal drugs, this segment still has the largest consumer base due to its known characteristics and efficacy. Women in menopausal transition prefer this type of medicine based on their previous experiences and routines due to its cheaper price. Moreover, fewer cases of adverse cases using these drugs are the reason behind making this therapy the top-selling contender. According to an article published by the American Heart Association, in February 2023, 80% of women aged 55 or less have a lower risk of having serious chronic side effects such as cardiovascular disease or breast cancer, accounting for ≥1.
Our in-depth analysis of the global vasomotor symptoms market includes the following segments:
|
Distribution Channel |
|
|
Therapy Type |
|
North America Market Analysis
North America in vasomotor symptoms market is set to capture over 50% revenue share by 2037 due to being the center of action for global leaders. Well-established healthcare infrastructure propels growth in this region. Better access to medical and financial support in developed countries ensures a sufficient supply of therapeutics for patients, creating a profitable marketplace for global leaders. For instance, in November 2020, Avion Pharmaceuticals, LLC signed a license and commercialization agreement with Aspen Pharmacare Holdings Ltd. for the expansion of its VMS product portfolio. The agreement gave the company rights to relaunch Cenestin tablets in 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, and 1.25 mg.
The U.S. vasomotor symptoms market is inflating due to the conjugate effect of the aging population and increasing VMS prevalence. According to a report published by the National Council of Aging, in June 2024, 31.9 million women aged 65 or over were counted in the U.S. in 2022. Another NLM report, published in May 2021 states, that the prevalence rate of moderate-to-severe VMS in this country was measured to be 34%. Global leaders often choose this country as their first step in globalization due to the huge consumer base.
Canada is accelerating its R&D efforts to mark significant progress in the vasomotor symptoms market. The country’s governing body is investing and releasing policies to prioritize women’s health, creating a supportive trading environment for this sector. For instance, in October 2022, the government of Canada launched the National Women’s Health Research Initiative (NWHRI) to eliminate gaps in access to all healthcare categories including genital. The initiative was funded by USD 20 million over 5-years investment made in the 2021 budget.
APAC Market Statistics
Asia Pacific is poised to experience the fastest growth in the vasomotor symptoms market during the forecast timeline. This landscape is growing with the increasing demand for prescription therapeutics to control such genital issues in the aging population. The strong emphasis on the pharmaceutical industry in developing countries such as China and India is making this region a global supplier of required therapeutics. According to a Research Nester report, APAC is anticipated to dominate the global estrogen receptor agonist industry, which is a crucial element in hormonal therapy for vasomotor symptoms.
India is registering a lucrative propagation in the vasomotor symptoms market due to its enlarging pharmaceutical industry. This is inspiring domestic leaders to explore a wider range of medical categories to broaden the diversity of this sector. According to the IBEF report, published in November 2024, the pharma industry in India is expected to garner a value of USD 130 billion by 2030 and USD 450 billion by 2047. The report further highlighted that the country consists of more than 10,500 manufacturing facilities to supply more than 150 countries across the globe.
China is also leveraging its production and resources of effective therapeutics to cope with the increasing burden of menopause-related health issues. This places the country among the top contributors to the growth of the regional vasomotor symptoms market. According to a report acquired from the study conducted by NLM on the older female population of China, published in August 2021, many chronic conditions are associated with menopausal symptoms. The report further stated that the prevalence of such symptoms including VMS in middle-aged women of this country was 9.3%, 23.9%, and 21.5% during the reproductive stage, menopausal transition, and postmenopausal stage respectively.
The leaders in the market are now highly focused on expanding their portfolio across the world. They are acquiring several regional approvals to ensure maximum adoption in all marketplaces. To earn lucrative profits from this emerging industry in women’s healthcare, they are conducting R&D projects and clinical studies to establish the effectiveness and safety of their offerings. For instance, in May 2024, Bayer announced the ground-breaking results of Phase III studies of OASIS 1 and 2 for the investigational compound elinzanetant at the ACOG annual meeting. The results showcased better efficacy and safety of this element in comparison to placebo for the treatment of vasomotor symptoms associated with menopause. Such key players include:
Author Credits: Radhika Pawar
Copyright © 2025 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?